Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that magnetic resonance imaging (MRI) of the breast continues to show double digit growth in 2008 and is one of the fastest growing procedures in the magnetic resonance departments. MRI of the breast is predominately performed to diagnose breast cancer.

"In the first half of 2008 the total number of patients undergoing MRI of the breast increased 23 percent over the same period in 2007," stated Anna Fisher, analyst at AMR. "This boost may be attributed to increased awareness campaigns for early detection and treatment of breast cancer."

The newly released edition of the Imaging Market Guide also finds that approximately 90 percent of patients undergoing an MRI of the breast received a contrast agent during the study to improve the delineation between normal and abnormal tissues.

Why Pharmaceutical and Medical Device Companies Need this Information

The Imaging Market Guide enables pharmaceutical and medical device companies to monitor the utilization rates of imaging devices in the U.S., Italy, Germany, France, U.K., Spain, China, Japan and Korea. It is the industry's most comprehensive data available to gauge movement and direction of the volume of imaging devices with iodinated contrast agent and radiopharmaceutical usage information in hospital and non-hospital settings.

About the Imaging Market Guide

The Imaging Market Guide is the industry's most comprehensive audit of conventional x-ray, CT scanning, MRI, ultrasound, nuclear medicine and cardiac cath lab procedure volumes, with iodinated contrast agent and radiopharmaceutical usage information in hospital and non-hospital settings. The information in this database is collected directly from end users-technologists, managers and supervisors working in hospital radiology and cardiology departments, vascular labs, cardiac cath labs, special procedure areas, free-standing imaging centers and private cardiologists' offices. The audit is conducted twice a year and covers the U.S., Italy, Germany, France, U.K., Spain, China, Japan and Korea.

About AMR

AMR (http://www.amr-data.com/) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Natalia Morales                           Elizabeth Marshall   Decision Resources                        Decision Resources, Inc.   781-296-2691                              781-296-2563   nmorales@dresources.com                   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Arlington Medical Resources

CONTACT: Natalia Morales, +1-781-296-2691, nmorales@dresources.com; or
Elizabeth Marshall, +1-781-296-2563, emarshall@dresources.com, both of
Decision Resources, Inc.

The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017

View Now